Keytruda’s MSI-H Cancer Use Up for MHLW Panel Review Nov. 29; Wider Hemlibra Indication, 1st Line Tecentriq Also on Agenda

MSD’s immuno-oncology star Keytruda (pembrolizumab) will come up for review by a key health ministry panel on November 29 as it seeks what would be Japan’s first nod for a tumor-agnostic, biomarker-based indication, which targets a gene mutation irrespective of...read more